Zentalis Pharmaceuticals, Inc. (ZNTL) is a publicly traded company in the Unknown sector. Across all available filings, 25 corporate insiders have executed 540 transactions totaling $244.3M, demonstrating a bearish sentiment with -$154.0K in net insider flow. The most recent transaction on Feb 10, 2026 involved a sale of 6,894 shares valued at $16.7K.
No significant insider buying has been recorded for ZNTL in the recent period.
No significant insider selling has been recorded for ZNTL in the recent period.
Based on recent SEC filings, insider sentiment for ZNTL is bearish with an Insider Alignment Score of 50/100 and a net flow of -$154.0K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Zentalis Pharmaceuticals, Inc. (ZNTL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 25 insiders are actively trading ZNTL stock, having executed 540 transactions in the past 90 days. The most active insider is Capital Management Company, Lp Matrix (Executive), who has made 1 transactions totaling $107.9M.
Get notified when executives and directors at ZNTL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Vultaggio Vincent | PAO and PFO | Sale | 6,894 | $2.42 | $16.7K | |
| Feb 9, 2026 | Marie Eastland Julia | Executive | Sale | 889 | $2.39 | $2.1K | |
| Feb 9, 2026 | Vultaggio Vincent | PAO and PFO | Sale | 3,379 | $2.39 | $8.1K | |
| Feb 9, 2026 | Bruns Ingmar | Chief Medical Officer | Sale | 335 | $2.39 | $802 | |
| Feb 6, 2026 | Marie Eastland Julia | Executive | Sale | 7,866 | $2.43 | $19.1K | |
| Feb 6, 2026 | Vultaggio Vincent | PAO and PFO | Sale | 29,951 | $2.43 | $72.8K | |
| Feb 6, 2026 | Bruns Ingmar | Chief Medical Officer | Sale | 2,962 | $2.43 | $7.2K | |
| Feb 3, 2026 | Vultaggio Vincent | PAO and PFO | Sale | 556 | $2.52 | $1.4K | |
| Feb 2, 2026 | Vultaggio Vincent | PAO and PFO | Sale | 2,540 | $2.55 | $6.5K | |
| Jan 8, 2026 | Marie Eastland Julia | Executive | Award | 775,000 | $N/A | $0 | |
| Jan 8, 2026 | Bruns Ingmar | Chief Medical Officer | Award | 365,000 | $N/A | $0 | |
| Jan 8, 2026 | B. Bucher James | Chief Legal Officer | Award | 100,000 | $N/A | $0 | |
| Jan 8, 2026 | Vultaggio Vincent | PAO and PFO | Award | 100,000 | $N/A | $0 | |
| Dec 15, 2025 | E. Goel David | Executive | Sale | 7,500,000 | $1.33 | $10.0M | Large |
| Jun 21, 2024 | Michael Johnson David | Executive | Award | 48,429 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 446 | $122.2M | 49.4% |
Purchase(P) | 10 | $122.1M | 49.3% |
Exercise(M) | 8 | $1.8M | 0.7% |
Payment(F) | 2 | $1.4M | 0.6% |
Award(A) | 55 | $0 | 0.0% |
Gift(G) | 18 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider activity at Zentalis Pharmaceuticals, Inc. shows mixed signals across all time. While $122.1M in purchases indicates some executive confidence,$122.2M in sales balances the picture, resulting in a modest net flow of -$154.0K.25 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Capital Management Company, Lp Matrix, has transacted $107.9M during this period.